Dutch Startup Raises €1.675 Million to Bring Hospital-Grade Heart Tests to Your Doctor's Office

2026-02-11 bio

Netherlands, Wednesday, 11 February 2026.
HeartEye’s breakthrough mobile ECG recorder enables general practitioners to perform comprehensive 12-channel heart diagnostics in under one minute, anywhere outside traditional hospital settings. This funding round attracted notable tech entrepreneurs including Schuberg Philis co-founder Pim Berger and positions the company to revolutionize cardiac care accessibility while reducing healthcare costs.

Healthtech Innovation Targeting Cardiovascular Mortality

This investment represents a significant development in the healthtech sector, specifically addressing cardiovascular diagnostics through mobile technology innovation [1]. HeartEye successfully completed its €1.675 million funding round on February 4, 2026, with participation from ROM InWest as the lead investor, alongside Schuberg Philis co-founder Pim Berger, Mphasis co-founder Jeroen Tas, and returning investor Health Innovations [1][3]. The Dutch startup’s patented mobile 12-channel ECG recorder aims to bring hospital-grade cardiac diagnostics directly to patients outside traditional hospital environments, addressing both mortality reduction from heart conditions and healthcare cost optimization [1]. The technology enables healthcare professionals to create comprehensive 12-channel electrocardiograms in less than one minute using a fully wireless, handheld device that can be operated by general practitioners, assistants, or nurses in various settings including family practices and nursing homes [1].

Revolutionary Cardiac Diagnostic Technology

HeartEye’s innovation fundamentally transforms the traditional ECG process, which currently requires trained professionals and complex, time-consuming procedures typically confined to hospital settings [1]. The company’s wireless ECG recorder enables rapid, simple heart film creation anywhere, supporting family practices and nursing homes in conducting cardiac diagnostics, with future plans for patients to perform these tests at home [1]. Through the integrated digital platform, healthcare providers can share ECG readings with physicians or specialists for interpretation and diagnostic support, facilitating earlier detection of heart problems and ensuring appropriate patients reach cardiologists promptly while preventing unnecessary hospital referrals [1]. This approach contributes to more efficient healthcare delivery, reduced costs, and decreased workload pressures on medical facilities [1]. Sara Schaafsma, Investment Manager at ROM InWest, emphasized the company’s strategic role in guiding HeartEye through the bridging phase, noting that venture capital partners typically enter after CE certification when market introduction and scaling become viable [8].

Strategic Investment and Development Roadmap

The €1.675 million capital injection addresses the critical funding gap that MedTech companies face during the pre-certification phase, when substantial investments are required but clinical usage and regular revenue generation are not yet permitted [1]. HeartEye will utilize the funding to conduct pivotal clinical studies and advance AI software development while enhancing the digital healthcare platform and establishing production capacity to meet anticipated demand following market approval [1]. Like other MedTech innovations, HeartEye must establish and certify its production processes according to current Medical Device Regulation (MDR) requirements, representing a time and capital-intensive period that this investment helps bridge [1]. ROM InWest identified its role as supporting companies through this challenging phase, particularly since venture capital firms typically invest either during prototype development or after CE certification when technological and market-related risks are significantly reduced and scaling opportunities emerge [1][4].

Market Impact and Regional Development Potential

ROM InWest, founded in 2021 and based in Haarlem, North Holland, focuses on connecting the regional ecosystem through investments in startups, scale-ups, and innovative small and medium enterprises that accelerate transitions in food, energy, healthcare, and circular economy sectors [4][5]. The investment firm manages both the MKB fund with €60 million and the Transition fund targeting €100 million in capital, providing financing ranging from €300,000 to €5 million for up to 49.9% of total equity or debt with maximum 15-year terms [4]. Schaafsma projects that HeartEye has substantial opportunities to grow into a leading player that stimulates high-quality employment and knowledge development in the region, particularly through collaboration with Amsterdam UMC [8]. The innovative ECG recorder delivers direct and sustainable contributions to healthcare future-proofing and affordability, positioning HeartEye to make significant regional economic impact while advancing cardiac care accessibility [1][8].

Bronnen

healthtech funding cardiac diagnostics